نتایج جستجو برای: tp53

تعداد نتایج: 8206  

2015
Ana-Iris Schiefer Christoph Kornauth Ingrid Simonitsch-Klupp Cathrin Skrabs Eva Katharina Masel Berthold Streubel Katrina Vanura Karin Walter Brigitta Migschitz Dagmar Stoiber Veronika Sexl Markus Raderer Andreas Chott Maria Gomes da Silva Jose Cabecadas Leonhard Müllauer Ulrich Jäger Edit Porpaczy

MYC and BCL2 translocations as well as TP53 deletion/mutation are known risk factors in diffuse large B-cell lymphoma (DLBCL) but their interplay is not well understood.In this retrospective cohort study, we evaluated the combined prognostic impact of TP53 deletion and mutation status, MYC and BCL2 genomic breaks in tumor samples of 101 DLBCL patients. The cohort included 53 cases with MYC rear...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007
Leah E Mechanic Elise D Bowman Judith A Welsh Mohammed A Khan Nobutoshi Hagiwara Lindsey Enewold Peter G Shields Laurie Burdette Stephen Chanock Curtis C Harris

Lung cancer is primarily caused by tobacco smoking, but susceptibility is likely modified by common genetic variation. In response to many forms of cellular stress, including DNA damage, the p53 protein functions to induce cell cycle arrest, DNA repair, senescence, or apoptosis. We hypothesized that common TP53 haplotypes modulate pathways of lung carcinogenesis and lung cancer susceptibility o...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Rossella Libè Lionel Groussin Frédérique Tissier Caroline Elie Fernande René-Corail Amato Fratticci Eric Jullian Paolo Beck-Peccoz Xavier Bertagna Christine Gicquel Jérôme Bertherat

PURPOSE Allelic losses [loss of heterozygosity (LOH)] at the 17p13 locus are frequent (85%) in adrenocortical cancers. The tumor suppressor gene TP53 is located at 17p13. The aim of the study was to determine the frequency of TP53 somatic inactivating mutations in adrenocortical tumors with 17p13 LOH and their clinico-biological correlations. EXPERIMENTAL DESIGN TP53 somatic mutations, intrag...

Journal: :Blood 2013
Annika Dufour Giuseppe Palermo Evelyn Zellmeier Gudrun Mellert Guillemette Duchateau-Nguyen Stephanie Schneider Tobias Benthaus Purvi M Kakadia Karsten Spiekermann Wolfgang Hiddemann Jan Braess Sim Truong Nancy Patten Lin Wu Sabine Lohmann David Dornan Debraj GuhaThakurta Ru-Fang Yeh Galina Salogub Philippe Solal-Celigny Anna Dmoszynska Tadeusz Robak Marco Montillo John Catalano Christian H Geisler Martin Weisser Stefan K Bohlander

In chronic lymphocytic leukemia (CLL) patients, disruptions of the TP53 tumor suppressor pathway by 17p13 deletion (del17p), somatic TP53 mutations, or downregulation of microRNA-34a have been associated with a poor prognosis. So far, the impact of the various TP53 defects has not been evaluated in a large cohort of previously treated and relapsed CLL patients. Here, we present the results of T...

ژورنال: طب جنوب 2018
انصاری‌فر, اکرم, ذاکرحسینی, مرضیه, طاهرخانی, رضا, طاهرخانی, سکینه, فرشادپور, فاطمه, مرادی‌نسب, مریم, نعیمی, سیروس,

زمینه: ژن سرکوبگر تومور TP53، در ترمیم آسیب‌های وارد شده به DNA و همچنین در آپوپتوزیس سلولی نقش دارد. این پژوهش به بررسی ارتباط بین پلی‌مورفیسم کدون 72 ژن TP53 در انواع نمونه‌های بافتی غیرطبیعی سرویکس در مقایسه با نمونه‌های زنان سالم به‌عنوان گروه کنترل و همچنین فراوانی ویروس‌های هرپس سیمپلکس انسانی در این نمونه‌ها پرداخته است. مواد و روش‌ها: در این مطالعه موردی- شاهدی، تعداد 110 نمونه بیوپس...

2018
Shigeo Yamaguchi Shin Takahashi Kaoru Mogushi Yuki Izumi Yumi Nozaki Tadashi Nomizu Yoichiro Kakugawa Takanori Ishida Noriaki Ohuchi Chikashi Ishioka Shunsuke Kato

Purpose TP53 signature has a robust predictive performance for prognosis in early-stage breast cancer, but the experiment that reported this relied on public microarray data and fresh-frozen samples. Before TP53 signature can be used in a clinical setting, a simple and low-cost diagnostic system using formalin-fixed paraffin-embedded (FFPE) samples is needed. New treatments based on the biologi...

Journal: :Blood 2012
Frank G Rücker Richard F Schlenk Lars Bullinger Sabine Kayser Veronica Teleanu Helena Kett Marianne Habdank Carla-Maria Kugler Karlheinz Holzmann Verena I Gaidzik Peter Paschka Gerhard Held Marie von Lilienfeld-Toal Michael Lübbert Stefan Fröhling Thorsten Zenz Jürgen Krauter Brigitte Schlegelberger Arnold Ganser Peter Lichter Konstanze Döhner Hartmut Döhner

To assess the frequency of TP53 alterations and their correlation with other genetic changes and outcome in acute myeloid leukemia with complex karyotype (CK-AML), we performed integrative analysis using TP53 mutational screening and array-based genomic profiling in 234 CK-AMLs. TP53 mutations were found in 141 of 234 (60%) and TP53 losses were identified in 94 of 234 (40%) CK-AMLs; in total, 1...

Journal: :International journal of oncology 2011
Birgitte L Adamsen Katherine L Kravik Paula M De Angelis

We studied patterns of DNA damage signaling and cell cycle response to clinically-relevant (bolus) and high doses of 5-fluorouracil (5-FU) in three colorectal cancer cell lines with differing MMR and TP53 status in an attempt to better understand how 5-FU exerts its cytotoxicity. The ATM/CHEK2/ CHEK1 signaling pathway was not activated in response to bolus 5-FU in the MMR-deficient cell lines H...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013
Nataliya Zhukova Vijay Ramaswamy Marc Remke Elke Pfaff David J H Shih Dianna C Martin Pedro Castelo-Branco Berivan Baskin Peter N Ray Eric Bouffet André O von Bueren David T W Jones Paul A Northcott Marcel Kool Dominik Sturm Trevor J Pugh Scott L Pomeroy Yoon-Jae Cho Torsten Pietsch Marco Gessi Stefan Rutkowski Laszlo Bognar Almos Klekner Byung-Kyu Cho Seung-Ki Kim Kyu-Chang Wang Charles G Eberhart Michelle Fevre-Montange Maryam Fouladi Pim J French Max Kros Wieslawa A Grajkowska Nalin Gupta William A Weiss Peter Hauser Nada Jabado Anne Jouvet Shin Jung Toshihiro Kumabe Boleslaw Lach Jeffrey R Leonard Joshua B Rubin Linda M Liau Luca Massimi Ian F Pollack Young Shin Ra Erwin G Van Meir Karel Zitterbart Ulrich Schüller Rebecca M Hill Janet C Lindsey Ed C Schwalbe Simon Bailey David W Ellison Cynthia Hawkins David Malkin Steven C Clifford Andrey Korshunov Stefan Pfister Michael D Taylor Uri Tabori

PURPOSE Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer conflicting conclusions. We resolve this issue through the inclusion of molecular subgroup profiles. PATIENTS AND METHODS We determined subgroup affiliation, TP53 mutation status, and clinical outcome in a discovery cohort of 397 medulloblastomas. We subsequently validated our results on an independent ...

2017
Agnieszka Sliwinska Jacek Kasznicki Marcin Kosmalski Melania Mikołajczyk Aneta Rogalska Karolina Przybylowska Ireneusz Majsterek Jozef Drzewoski

BACKGROUND & OBJECTIVES Tumour protein p53 (TP53) is a stress sensitive transcription factor responsible for the control of cell survival and death to prevent from tumour formation. In vitro and animal studies have indicated that TP53 also responds to metabolic changes and influences metabolic pathways. This study was undertaken to determine the serum level of TP53 and its correlations with cli...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید